Press Resease

Insulin Analog 1 Diabetes Market by Insulin Analog (Rapid-Acting Insulin Analogs, Long-Acting Insulin Analogs [Aspart, Glulisine, and Lyspro], and Premix Insulin Analogs), and by Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 - 2026

Published Date: 17-Oct-2020 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-2920 Status : Published

According to the report, global demand for insulin analog 1 diabetes market was valued at approximately USD 5,796.3 Million in 2019, and is expected to generate revenue of around USD 9,742.3 Million by end of 2026, growing at a CAGR of around 7.7% between 2020 and 2026.

Description

According to the report, global demand for insulin analog 1 diabetes market was valued at approximately USD 5,796.3 Million in 2019, and is expected to generate revenue of around USD 9,742.3 Million by end of 2026, growing at a CAGR of around 7.7% between 2020 and 2026.

Type 1 diabetes is a multifactorial chronic and autoimmune condition during which the body produces little or no insulin in the pancreas. Insulin hormone is needed by the body to get glucose from the bloodstream into the cells to produce energy. Most of the diabetes cases can be classified as type 1a – autoimmune disease, where the destruction of pancreatic beta cells is observed, low production of insulin disrupts blood glucose homeostasis and minor cases of type 1b – idiopathic diabetes mellitus. This type of diabetes is rare and develops during childhood or adolescence, but can also be seen in adults. Frequent urination, excessive thirst, increased hunger, weight loss, and fatigue are some of the typical symptoms. Diabetes diagnostic devices encompass test strips, lancets, analog blood meter along with insulin delivery devices such as insulin syringe, insulin pump, insulin pen and insulin jet injectors.

The global type 1 diabetes market is expected to bolster at a significant growth rate over the forecast period due to the decisive use of insulin for treatment of the disease along with increasing use of insulin delivery apparatus. Unhealthy food habits, rising obesity rates, and sedentary lifestyle are key contributing factors fueling the growth of global type 1 diabetes market. Government initiatives for diabetes control, the economic impact of the disease on the healthcare systems of several countries calls for growth of the market. Whereas, hostile reimbursement policies and high costs of diagnosis and treatment are restraining factors for the growth of global type 1 diabetes market. The innovation of newer molecules from newer class of diabetic drugs along with a strong pipeline would be an opportunity for growth along with an extension in development of non-invasive diabetes diagnostics and drug delivery devices can also be seen as an opportunity. Considering the side effects associated with the treatment therapies of type 1 diabetes could be seen as a challenge for the growth of the market.

The report covers forecast and analysis of the insulin analog 1 diabetes market on a global and regional level. The study provides historic data of 2016 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million). To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the aircraft engine market has also been included in the study. The report also analyzes several driving and restraining factors and their impact on the market during the forecast period. The study encompasses a market attractiveness analysis, wherein insulin analog segments are benchmarked based on their market size, growth rate and general attractiveness.

Global type 1 diabetes market is segmented on the basis of insulin analog as rapid-acting insulin analogs, long-acting insulin analogs, and premix insulin analogs. Rapid-acting insulin segment is further classified into aspart, glulisine, and lyspro. Rapid action segment is anticipated to expand at a significant growth rate over the forecast period attributed to increased uptake of the novel formulations.

Regionally, the insulin analog 1 diabetes market is divided into Europe, Latin America, Asia Pacific, North America, and the Middle East and Africa. Among the aforementioned regions, type 1 diabetes market is dominated in North America owing to increasing cases of diabetes in the region. The U.S. is emerging as the power market with a significant number of children below fourteen years who have type 1 diabetes compared to other countries in the region. Asia-Pacific is expected to record the substantial growth rate during the forecast period attributed to rise in the aging population in the region, with India emerging as the potential leader for the market within a forecast period.

Some of the players of insulin analog 1 diabetes market included in report are Eli Lilly and Company, Bayer Pharmaceuticals, Sanofi, Novo Nordisk, AstraZeneca Plc, XOMA Corp., DiaVacs, Inc., B. Braun Melsungen AG, Biodel, Inc., Macrogenics, Inc., and Takeda Pharmaceutical among others.

The report segments the global insulin analog 1 diabetes market into:

Global Insulin Analog 1 Diabetes Market: Insulin Analog Segment Analysis

  • Rapid-Acting Insulin Analogs
    • Aspart
    • Glulisine
    • Lyspro
  • Long-Acting Insulin Analogs
  • Premix Insulin Analogs

Global Insulin Analog 1 Diabetes Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodulogy
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodulogy
  • Chapter 2. Executive Summary
    • 2.1. Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
    • 2.2. Insulin Analog 1 Diabetes Market: Snapshot
  • Chapter 3. Insulin Analog 1 Diabetes Market – Industry Analysis
    • 3.1. Insulin Analog 1 Diabetes Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of type-1 diabetes due to environmental and genetic factors
      • 3.2.2. Government support for the treatment of type-1 diabetes
    • 3.3. Restraints
      • 3.3.1. Stringent approvals process that varies from nation to nation
    • 3.4. Opportunities
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by Insulin Analog
      • 3.6.2. Market attractiveness analysis by Region
  • Chapter 4. Insulin Analog 1 Diabetes Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Insulin Analog 1 Diabetes Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New product launches
      • 4.2.3. Agreements, partnerships, cullaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  • Chapter 5. Global Insulin Analog 1 Diabetes Market – Insulin Analog Analysis
    • 5.1. Global Insulin Analog 1 Diabetes Market overview: by Insulin Analog
      • 5.1.1. Global Insulin Analog 1 Diabetes Market share, by Insulin Analog, 2019 and 2026
    • 5.2. Rapid-Acting Insulin Analogs
      • 5.2.1. Global Insulin Analog 1 Diabetes Market by Rapid-Acting Insulin Analogs, 2016 – 2026 (USD Million)
      • 5.2.2. Aspart
        • 5.2.2.1. Global Aspart in Insulin Analog 1 Diabetes Market by Rapid-Acting Insulin Analogs, 2016 – 2026 (USD Million)
      • 5.2.3. Glulisine
        • 5.2.3.1. Global Glulisine in Insulin Analog 1 Diabetes Market by Rapid-Acting Insulin Analogs, 2016 – 2026 (USD Million)
      • 5.2.4. Lyspro
        • 5.2.4.1. Global Lyspro in Insulin Analog 1 Diabetes Market by Rapid-Acting Insulin Analogs, 2016 – 2026 (USD Million)
    • 5.3. Long-Acting Insulin Analogs
      • 5.3.1. Global Insulin Analog 1 Diabetes Market by Long-Acting Insulin Analogs, 2016 – 2026 (USD Million)
    • 5.4. Premix Insulin Analogs
      • 5.4.1. Global Insulin Analog 1 Diabetes Market by Premix Insulin Analogs, 2016 – 2026 (USD Million)
  • Chapter 6. Global Insulin Analog 1 Diabetes Market - Regional Analysis
    • 6.1. Global Insulin Analog 1 Diabetes Market overview: by Region
      • 6.1.1. Global Insulin Analog 1 Diabetes Market share, by Region, 2019 and 2026
    • 6.2. North America
      • 6.2.1. North America Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
      • 6.2.2. North America Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
      • 6.2.3. North America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.2.4. U.S.
        • 6.2.4.1. U.S. Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.2.5. Rest of North America
        • 6.2.5.1. Rest of North America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
    • 6.3. Europe
      • 6.3.1. Europe Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
      • 6.3.2. Europe Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
      • 6.3.3. Europe Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.3.4. U.K.
        • 6.3.4.1. U.K. Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.3.5. France
        • 6.3.5.1. France Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.3.6. Germany
        • 6.3.6.1. Germany Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.3.7. Rest of Europe
        • 6.3.7.1. Rest of Europe Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
      • 6.4.2. Asia Pacific Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
      • 6.4.3. Asia Pacific Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.4.4. China
        • 6.4.4.1. China Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.4.5. Japan
        • 6.4.5.1. Japan Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.4.6. India
        • 6.4.6.1. India Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.4.7. Rest of Asia Pacific
        • 6.4.7.1. Rest of Asia Pacific Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
    • 6.5. Latin America
      • 6.5.1. Latin America Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
      • 6.5.2. Latin America Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
      • 6.5.3. Latin America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.5.4. Brazil
        • 6.5.4.1. Brazil Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.5.5. Rest of Latin America
        • 6.5.5.1. Rest of Latin America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
    • 6.6. The Middle East and Africa
      • 6.6.1. The Middle East and Africa Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
      • 6.6.2. The Middle East and Africa Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
      • 6.6.3. The Middle East and Africa Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.6.4. GCC Countries
        • 6.6.4.1. GCC Countries Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.6.5. South Africa
        • 6.6.5.1. South Africa Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.6.6. Rest of Middle East & Africa
        • 6.6.6.1. Rest of Middle East & Africa Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
  • Chapter 7. Company Profiles
    • 7.1. Eli Lilly and Company
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfulio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Bayer Pharmaceuticals
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfulio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Sanofi
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfulio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Novo Nordisk
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfulio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. AstraZeneca Plc
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfulio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. XOMA Corp.
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfulio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. DiaVacs, Inc.
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfulio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. B. Braun Melsungen AG
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfulio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. Biodel, Inc.
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfulio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development
    • 7.10. Macrogenics, Inc.
      • 7.10.1. Overview
      • 7.10.2. Financials
      • 7.10.3. Product Portfulio
      • 7.10.4. Business Strategy
      • 7.10.5. Recent Development
    • 7.11. Takeda Pharmaceutical
      • 7.11.1. Overview
      • 7.11.2. Financials
      • 7.11.3. Product Portfulio
      • 7.11.4. Business Strategy
      • 7.11.5. Recent Development

Methodology

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social